A Phase 1 interventional study of Ertugliflozin 2 mg single dose and Ertugliflozin 2 mg split into twice daily in Diabetes Mellitus, Type 2 and Adult, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 1, and was the 2nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 124th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 55 in phase 1, and was the 95th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using 2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and the pharmacokinetic (PK) of single day dosing of 2 mg and 4 mg doses of ertugliflozin (Ertu, PF-04971729/MK-8835) each administered once vs twice daily (morning [AM] and evening [PM]) in adults with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
Drug: Ertugliflozin 2 mg single dose · Drug: Ertugliflozin 2 mg split into twice daily · Drug: Placebo
Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
Drug: Ertugliflozin 2 mg single dose · Drug: Ertugliflozin 2 mg split into twice daily · Drug: Placebo
Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
Drug: Ertugliflozin 4 mg single dose · Drug: Ertugliflozin 4 mg split into twice daily · Drug: Placebo
Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
Drug: Ertugliflozin 4 mg single dose · Drug: Ertugliflozin 4 mg split into twice daily · Drug: Placebo
Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
Placebo to ertugliflozin administered as a single dose
Cumulative Urinary Glucose Excretion Over 0 to 24 Hours
Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.
Time frame: 0 to 24 hours after the morning dose
Urinary Glucose Excretion by Time Period
Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.
Time frame: At 0-4 hrs, 4-8 hrs, 8-12 hrs, and 12-24 hrs after the AM dose (up to 24 hours)
24-hour Weighted Mean Plasma Glucose
Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.
Time frame: Up to 24 hours
Weighted Mean Postprandial Plasma Glucose
The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.
Time frame: At 0-5 hours, 5-12 hrs, and 12-18 hrs after the morning dose (up to 18 hours)
Fasting Plasma Glucose
Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.
Time frame: Up to 24 hours
Fasting C-peptide
The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.
Time frame: Up to 24 hours (0 and 24 hours)
Number of Participants Experiencing an Adverse Event
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.
Time frame: Up to 16 days
Number of Participants Discontinuing Study Drug Due to an Adverse Event
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.
Time frame: Up to 8 days (Day 1 in each dosing period)
Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin
Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.
Time frame: 0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose
Maximum Plasma Concentration (Cmax) of Ertugliflozin
PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.
Time frame: 0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose
Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin
PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.
Time frame: 0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose
| Milestone | Cohort 1: Ertu 2 mg/Pbo→Ertu 1 mg/Ertu 1 mg | Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo | Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg | Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/P |
|---|---|---|---|---|
| Started | 13 | 13 | 13 | 13 |
| Completed | 12 | 13 | 13 | 13 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Cohort 1: Ertu 2 mg/Pbo→Ertu 1 mg/Ertu 1 mg | Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo | Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg | Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/P |
|---|---|---|---|---|
| Started | 12 | 13 | 13 | 13 |
| Completed | 12 | 13 | 12 | 13 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.
| Grams | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Cumulative Urinary Glucose Excretion Over 0 to 24 Hours | 69.45 ± 9.08 | 70.43 ± 9.08 | 78.29 ± 9.77 | 80.54 ± 9.81 |
Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.
| Grams | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| 0 to 4 hours post dose | 12.88 ± 14.66 | 14.03 ± 11.63 | 14.66 ± 11.81 | 16.34 ± 10.16 |
| 4 to 8 hours post dose | 15.42 ± 12.00 | 17.87 ± 12.60 | 16.97 ± 11.64 | 19.78 ± 14.02 |
| 8 to 12 hours post dose | 14.47 ± 8.84 | 11.99 ± 7.70 | 14.30 ± 10.52 | 12.91 ± 6.93 |
| 12 to 24 hours post dose | 26.76 ± 20.10 | 26.31 ± 21.11 | 31.47 ± 22.71 | 32.94 ± 21.08 |
Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.
| mg/dL | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| 24-hour Weighted Mean Plasma Glucose | 173.6 ± 26.94 | 175.7 ± 29.88 | 169.1 ± 35.91 | 170.4 ± 41.26 |
The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.
| mg/dL | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| 0 to 5 hours | 200.1 ± 38.27 | 187.2 ± 41.37 | 194.1 ± 46.87 | 189.9 ± 53.17 |
| 5 to 12 hours | 159.4 ± 25.76 | 159.8 ± 28.46 | 160.5 ± 42.14 | 161.5 ± 40.70 |
| 12 to 18 hours | 180.7 ± 35.98 | 190.7 ± 35.38 | 182.6 ± 40.79 | 181.9 ± 40.79 |
Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.
No measurements were reported for this outcome.
The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.
| ng/mL | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Fasting C-peptide | 2.82 ± 1.148 | 2.76 ± 0.997 | 3.00 ± 0.916 | 2.99 ± 0.973 |
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.
| Participants | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Number of Participants Experiencing an Adverse Event | 5 | 8 | 3 | 5 |
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.
| Participants | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Number of Participants Discontinuing Study Drug Due to an Adverse Event | 0 | 1 | 0 | 0 |
Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.
| ng*hr/mL | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin | 131.8 ± 26 | 132.7 ± 28 | 272 ± 19 | 270.5 ± 20 |
PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.
| ng/mL | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Ertugliflozin | 19.51 ± 39 | 26.98 ± 37 | 34.80 ± 23 | 50.83 ± 25 |
PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.
| hours | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin | 6.00 (0.500 to 12.0) | 1.00 (0.500 to 5.50) | 6.00 (0.500 to 8.00) | 1.00 (0.500 to 6.00) |
Collected over Up to 16 days (including 7-day follow-up for each period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Ertugliflozin 1 mg Twice Daily | 0/25 (0%) | 0/25 (0%) | 5/25 (20%) |
| Cohort 1: Ertugliflozin 2 mg Once Daily | 0/26 (0%) | 0/26 (0%) | 8/26 (30.8%) |
| Cohort 2: Ertugliflozin 2 mg Twice Daily | 0/26 (0%) | 0/26 (0%) | 3/26 (11.5%) |
| Cohort 2: Ertugliflozin 4 mg Once Daily | 0/26 (0%) | 0/26 (0%) | 5/26 (19.2%) |
| Event | Cohort 1: Ertugliflozin 1 mg Twice Daily | Cohort 1: Ertugliflozin 2 mg Once Daily | Cohort 2: Ertugliflozin 2 mg Twice Daily | Cohort 2: Ertugliflozin 4 mg Once Daily |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/25 | 3/26 | 1/26 | 2/26 |
| DiarrhoeaGastrointestinal disorders | 0/25 | 0/26 | 1/26 | 3/26 |
| DyspepsiaGastrointestinal disorders | 1/25 | 0/26 | 0/26 | 0/26 |
| FatigueGeneral disorders | 1/25 | 1/26 | 0/26 | 0/26 |
| Increased appetiteMetabolism and nutrition disorders | 1/25 | 0/26 | 0/26 | 0/26 |
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 0/26 | 0/26 | 0/26 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/25 | 1/26 | 0/26 | 0/26 |
| Skin irritationSkin and subcutaneous tissue disorders | 1/25 | 0/26 | 0/26 | 0/26 |
| Eye painEye disorders | 0/25 | 0/26 | 1/26 | 0/26 |
| Vision blurredEye disorders | 0/25 | 1/26 | 0/26 | 0/26 |
All randomized participants.
| Age, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| 18 - 44 years | 7 | 7 | 14 |
| 45 - 64 years | 17 | 18 | 35 |
| 65 years or older | 2 | 1 | 3 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 22 | 23 | 45 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2010 to primary completion in Apr 2010, 1 month.
Results were first posted in Nov 2018, 8 years 7 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin